35
Participants
Start Date
February 6, 2019
Primary Completion Date
August 18, 2021
Study Completion Date
September 14, 2022
Emapalumab
Emapalumab will be administered by intravenous infusion, twice weekly.
Karolinska University Hospital Huddinge, Stockholm
Istituto Giannina Gaslini, Genova
Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology, Wilmington
Universitätsklinikum Eppendorf, Hamburg
Fondazione MBBM, Ospedale San Gerardo, Monza
Hospital Universitario Niño Jesús, Madrid
Children's Healthcare of Atlanta, Atlanta
Ospedale della Donna e del Bambino, Verona
Universitätsklinikum Essen, Essen
Cincinnati Children's Hospital, Cincinnati
Spectrum Health Helen DeVos Children's Hospital, Grand Rapids
Texas Children's Hospital - Feigin Center, Houston
Medical Center- University of Freiburg, Freiburg im Breisgau
Phoenix Children Hospital, Phoenix
Children's Hospital Los Angeles, Los Angeles
Seattle Children's Hospital, Seattle
Children's Hospital Colorado, Aurora
Dana-Farber Cancer Institute (DFCI), Boston
Hopital Ste-Justine Research Center, Montreal
Hospital for Sick Children, Toronto
Children's and Women's Health Centre of British Columbia, Vancouver
Ospedale Pediatrico Bambino Gesù, Rome
Hospital Universitario Vall d'Hebron, Barcelona
University Children's Hospital Zurich, Zurich
Leeds Children's Hospital, Leeds
Great Ormond Street Hospital, London
Royal Manchester Children's Hospital, Manchester
Lead Sponsor
Swedish Orphan Biovitrum
INDUSTRY